Autoimmune Encephalitis Clinical Trial
Official title:
A Prospective Study to Evaluate Clinical Outcomes in Patients With Anti-leucine-rich Glioma-inactivated 1 Encephalitis
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases. So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.
In this prospective study, the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis. At the acute stage and during the follow-up, some routine and advanced paraclinical examinations will be conducted, including dynamic blood and/or cerebrospinal fluid (CSF) test, multimodal brain magnetic resonance imaging (MRI) including functional MRI, diffusion tensor imaging, arterial spin labeling, et al), Electroencephalography (EEG) or continuous video-EEG (VEEG), positron emission tomography (PET), neuropsychological tests and some other paraclinical examinations. Through the comprehensive analysis, the clinical outcomes and associated factors are further explored in anti-LGI1 encephalitis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
| Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
| Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
| Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
| Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
| Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
| Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
| Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
| Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
| Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
| Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
| Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
| Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
| Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
| Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
| Not yet recruiting |
NCT06456736 -
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
|
||
| Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|